Mutations in Hemagglutinin and Polymerase Alter the Virulence of Pandemic A(H1N1) Influenza Virus
- Autores: Gambaryan A.S.1, Lomakina N.F.1,2, Boravleva E.Y.1, Mochalova L.V.3, Sadykova G.K.2, Prilipov A.G.2, Matrosovich T.Y.4, Matrosovich M.N.4
-
Afiliações:
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
- Gamaleya Scientific Research Institute of Epidemiology and Microbiology
- All-Russia Institute for Scientific and Technical Information (VINITI)
- Institute of Virology
- Edição: Volume 52, Nº 4 (2018)
- Páginas: 556-569
- Seção: Molecular Cell Biology
- URL: https://journal-vniispk.ru/0026-8933/article/view/163610
- DOI: https://doi.org/10.1134/S0026893318040052
- ID: 163610
Citar
Resumo
To study the pathogenicity factors of the pandemic A(H1N1) influenza virus, a number of mutant variants of the A/Hamburg/5/2009 (H1N1)pdm09 strain were obtained through passage in chicken embryos, mouse lungs, and MDCK cell culture. After 17 lung-to-lung passages of the A/Hamburg/5/2009 in mice, the minimum lethal dose of the derived variant decreased by five orders of magnitude compared to that of the parental virus. This variant differed from the original virus by nine amino acid residues in the following viral proteins: hemagglutinin (HA), neuraminidase (NA), and components of the polymerase complex. Additional passaging of the intermediate variants and cloning made it possible to obtain pairs of strains that differed by a single amino acid substitution. Comparative analysis of replicative activity, receptor specificity, and virulence of these variants revealed two mechanisms responsible for increased pathogenicity of the virus for mice. Thus, (1) substitutions in HA (Asp225Gly or Gln226Arg) and compensatory mutation decreasing the charge of HA (Lys123Asn, Lys157Asn, Gly158Glu, Asn159Asp, or Lys212Met) altered viral receptor-binding specificity and restored the functional balance between HA and NA; (2) Phe35Leu substitution in the PA protein increased viral polymerase activity.
Palavras-chave
Sobre autores
A. Gambaryan
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Autor responsável pela correspondência
Email: al.gambaryan@gmail.com
Rússia, Moscow, 108819
N. Lomakina
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products; Gamaleya Scientific Research Institute of Epidemiology and Microbiology
Email: al.gambaryan@gmail.com
Rússia, Moscow, 108819; Moscow, 123098
E. Boravleva
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Email: al.gambaryan@gmail.com
Rússia, Moscow, 108819
L. Mochalova
All-Russia Institute for Scientific and Technical Information (VINITI)
Email: al.gambaryan@gmail.com
Rússia, Moscow, 125315
G. Sadykova
Gamaleya Scientific Research Institute of Epidemiology and Microbiology
Email: al.gambaryan@gmail.com
Rússia, Moscow, 123098
A. Prilipov
Gamaleya Scientific Research Institute of Epidemiology and Microbiology
Email: al.gambaryan@gmail.com
Rússia, Moscow, 123098
T. Matrosovich
Institute of Virology
Email: al.gambaryan@gmail.com
Alemanha, Marburg, 35043
M. Matrosovich
Institute of Virology
Email: al.gambaryan@gmail.com
Alemanha, Marburg, 35043
Arquivos suplementares
